In another series of experiments, we investigated the therapeutic efficacy of the NP-encapsulated SN22-TOx, NP[SN22-TOx], in the settings of MYCN-amplified disease, comparing the magnitude and longevity of responses in preclinical models of newly diagnosed and relapsed, multidrug-resistant NB featuring an acquired loss-of-function mutation in the tumor suppressor protein p53. The gene discussed is TP53; the disease is neuroblastoma.